Generic Drugs for Prostate Cancer to Escalate Market Growth

Patent expiries of prostate cancer drugs are expected to generate significant potential for players operating in the cancer generics sector, says RNCOS.

NOIDA, India (prHWY.com) March 8, 2013 - According to a new report by RNCOS, "Cancer Generics Market Analysis", the global cancer generics market has been advancing at a robust pace over the past few years. Patent expiries of blockbuster branded drugs support the growth of this market in a significant manner, thereby fetching billion of dollars. Moreover, the future holds enormous growth potential for the sector as there are many drugs under development stage. In such a scenario, the market for cancer generics is expected to grow at a healthy CAGR of around 26% during 2011-2015.

Our research report has found that prostate cancer is the second most regularly diagnosed cancer in men and the fifth most widespread cancer in general. Incidence rates for prostate cancer are on a rise. The future holds tremendous growth for prostate cancer generics as key drugs, such as Leuplin (Abbott) and Eligard (QLT Inc) are likely to loose their patent in a decade. This will generate a multi-billion dollar market for prostate cancer generics players.

The report, which is spread in over 70 pages, covers all the key aspects of the global cancer generics market taking into account all the factors that are responsible for the current and future growth. It investigates the current market drivers and trends that are likely to impact the future developments in the US NIPD sector. Further, it also evaluates the current status and future potential of generic drugs in most common cancers worldwide, such as lung cancer, breast cancer, colon cancer, stomach cancer, and prostate cancer.

The report is an outcome of an extensive research and in-depth analysis of the current status and expected position of the global cancer generics market. It illustrates the market drivers, key developments, and restraints that may impact the market in an effective manner. A brief description of active market players, such as Teva, Accord Healthcare, Mylan, and Sun Pharmaceuticals has also been provided. Overall, the report is an optimum source of knowledge and statistics for the clients interested to enter or expand in cancer generics market.

For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM353.htm

Some of our Related Reports are:

- Japan Generics Market Analysis (http://www.rncos.com/Report/IM371.htm)
- Generic Drug Market in Canada (http://www.rncos.com/Report/IM598.htm)
- Booming Generics Drug Market in India (http://www.rncos.com/Report/IM256.htm)
- UK Generics Market Analysis (http://www.rncos.com/Report/IM313.htm)
- Booming US Generic Drug Market (http://www.rncos.com/Report/IM589.htm)

Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm

About RNCOS

RNCOS specializes in Industry intelligence and creative solutions for contemporary business segments. Our professionals analyze the industry and its various components, with a comprehensive study of the changing market behavior. Our accuracy and data precision proves beneficial in terms of pricing and time management that assist the intending consultants in meeting their objectives in a cost-effective and timely manner.

###

Tag Words: cancer generics market

Categories: Health

Press Release Contact
B-129, Sector 6 Noida - 201301
91-120-4224-700
91-120-4224-707

Link To This Press Release:

URL HTML Code